Working… Menu

A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04379271
Recruitment Status : Completed
First Posted : May 7, 2020
Last Update Posted : April 26, 2021
FGK Clinical Research GmbH
Information provided by (Responsible Party):
Immunic AG

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : January 12, 2021
Actual Study Completion Date : February 23, 2021